You may have heard about Ozempic, Wegovy and Mounjaro. It\u2019s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of weight. That\u2019s leading to big sales for drug companies and helping change the way we think about weight loss. WSJ\u2019s Ariana Aspuru digs into how these drugs work, the big money involved and what it means for millions of Americans who meet the criteria for obesity.\xa0\n\n\n\nFurther reading:\xa0\n\nPill for Obesity Has Wall Street Salivating\xa0\n\nWill Ozempic Change \u2018Body Positivity\u2019 for Good?\xa0\n\nNo More Shots: Pill Versions of Ozempic-Like Drugs Are Coming\xa0\n\nThe Drugs That Are Gaining on Ozempic\xa0\n\nLearn more about your ad choices. Visit megaphone.fm/adchoices